Slide 1: Q2 2025 Interim Report
Q2 2025 Interim Report Senzime AB (publ.) April-June 2025
Slide 2: First half of 2025: 90% sales growth in local currencies
First half of 2025: 90% sales growth in local currencies Net sales increased by 82% to 49.2 million SEK (27.0), Jan-June 2025 revenues (MSEK) 1 and 90% in local currencies. Sales boosted by Next-gen 50 TetraGraph and TetraSens 45 Deliveries of disposable sensors (units) grew 101% driven 40 2 by recu
Slide 3: We continue to be one of the fastest growing medical device companies on Nasdaq Stockholm
We continue to be one of the fastest growing medical device companies on Nasdaq Stockholm Net sales rolling 12-months (kSEK) Net sales per quarter (kSEK) 90,000 30,000 80,000 25,000 70,000 60,000 20,000 50,000 15,000 40,000 30,000 10,000 20,000 5,000 10,000 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 4: Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors
Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors Total delivered units of TetraGraph systems 727 TetraGraphs delivered 4,500 during Q2 4,000 3,500 3,000 Next-Generation 2,500 2,000 1,500 1,000 500 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2023 2024 2025 4
Slide 5: Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors
Our installed base of TetraGraph monitors keeps growing, driving sales of disposable sensors Shipped sensors (units) by month ‘22 - June ‘25 45,000 40,000 327,215 (153,365) TetraSens sensors sold 35,000 last 12 months 30,000 25,000 20,000 15,000 10,000 5,000 0 Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr
Slide 6: Product and market mix: Strong growth in all sectors
Product and market mix: Strong growth in all sectors Jan-June 2025 Currency Reported adjusted kSEK 2025 2024 Growth Growth Split sales per product group Split sales per region US 35 481 20 011 77% 86% Europe Instruments/other 16 307 8 959 82% 92% 14% Instru- Sensors 19 174 11 051 73% 80% ments Europ
Slide 7: US market progression
US market progression Sales in local USD currency (kUSD) in US market 2,500 • 4x increase in sales since we initiated clear US focus in 2023 (Jan-Jun 2025 vs. Jan-Jun 2023). The result 101% of team expansion, focus and key wins 2,000 sales growth Q2 vs. Q2 2024. • Secured approx. 200 hospital accoun
Slide 8: Selected key US TetraGraph installations Q2 2025
Selected key US TetraGraph installations Q2 2025 Pacific North-West based hospital system Northern MidWest based Contract includes an initial order of 65 next- generation TetraGraph systems for hospital system monitoring patients under neuromuscular Installation of 80 Next-Gen block for use at multi
Slide 9: Tariffs and currencies affect Gross Margin in Q2
Tariffs and currencies affect Gross Margin in Q2 Gross Margin YTD increased to 63.8% (63.7%) Reported Gross Margin Q2 61.7% despite US tariffs and negative currency effects. Positive effects from lower production costs US tariff effect -1.5% Q2 Gross Margin was 61.7% hit by new US-tariffs, Next-Gen
Slide 10: Rapid sales growth combined with stable operating expenses
Rapid sales growth combined with stable operating expenses Quarterly Direct Operating Expenses (KSEK) 50,000 • Q2 direct OPEX of 40,361 kSEK 45,000 41,053 41,367 (39,573) in-line with plans despite 39,573 40,361 40,000 36,930 37,337 significant investments in US 36,429 34,419 commercial team and glo
Slide 11: Progression towards profitability
Progression towards profitability Quarterly EBITDA (KSEK) 18% 0 • Q2 EBITDA improved by 18% to -23,573 kSEK (-28,858) -5,000 mainly driven by higher sales and stable OPEX improvement of -10,000 EBITDA in Q2 • Q2 Cash flow from operations improved to -25,348 kSEK -15,000 (-30,884), including changes
Slide 12: Long-term Funding Secured
Long-term Funding Secured • Raise of 110.4 MSEK by issue of 24 million new shares at SEK 4.60 per share, corresponding to market price. • Investors included a group of new institutional investors including Unionen (Sweden’s largest trade union), Protean and ShapeQ GmbH, as well as existing and long-
Slide 13: Shareholding update, June 30th, 2025
Shareholding update, June 30th, 2025 Q2 2025 Largest shareholders End of Q2 2025 End of Q1 2025 End of Q4 2024 End of Q3 2024 vs. Q3 2024 Crafoord family and the Crafoord Foundation 25 196 551 16,1% 22 644 051 17,0% 22 644 051 17,0% 20 222 151 16,9% 4 974 400 Segulah Venture AB, Segulah AB, SMA 15 8
Slide 14: Pre-announcement of European Pediatric Guidelines for Neuromuscular Monitoring
Pre-announcement of European Pediatric Guidelines for Neuromuscular Monitoring • Pediatric patients (approx. 10-12 million per year) receive paralytic drugs and are not adequately monitored during surgery due to lack of guidelines and historical limitations in monitoring technology • Without monitor
Slide 15: Expansion of partnership with Fukuda Denshi
Expansion of partnership with Fukuda Denshi • Senzime’s Licensee Fukuda Denshi Expands Market Reach with FDA and UKCA Regulatory Approvals for its NMT-module powered by TetraGraph-technology • Opens for launch in UK and US of integrated HN-100 neuromuscular transmission module – with potential for s
Slide 16: Key take-aways
Key take-aways 1 2 3 HYPER GROWTH WE’RE WINNING BIG BUILDING BLOCKS IN PLACE • 90% growth in local currencies • Strong demand for next-gen • Guidelines in place and driven by recurring sales of TetraGraph, and its ease-of-use more to come sensors as well as monitors expands market opportunity • Back
Slide 17: Revolutionizing perioperative care. Smart and simple.
Revolutionizing perioperative care. Smart and simple. Our mission is to safeguard every patient's journey, from anesthesia to recovery. We do this by developing user-friendly precision-based monitoring solutions, based on decades of science, that drive a perioperative digital transformation. Our com